Difficulty: Medium
Average Score: 95%
Practice
A 65-year-old man with end-stage renal disease because of diabetes recently underwent a renal transplant. He has been responding well to the transplant and his creatinine has stabilized around 2.1 mg/dL. He was placed on immunosuppressive therapy with muromonab. What is the mechanism of action of muromonab?
Correct answer
A
Rationale
The correct answer is A) Binds to CD3 on T cells. Muromonab, also known as OKT3, is a monoclonal antibody that targets and binds to the CD3 receptor on T cells. By binding to CD3, muromonab inhibits the function of T cells, specifically blocking T cell activation and proliferation. This mechanism of action is crucial in the context of organ transplantation to prevent T cell-mediated rejection of the transplant.
Option B) Binds to FK-binding protein is incorrect because this mechanism refers to drugs like tacrolimus and cyclosporine, which act by inhibiting calcineurin and preventing the production of interleukin-2 (IL-2).
Option C) Binds to IL-2 receptors on T cells is incorrect because muromonab does not directly target IL-2 receptors but rather binds to CD3 to block T cell activation, subsequently affecting IL-2 production.
Option D) Binds to mTOR is incorrect because this mechanism refers to drugs like sirolimus and everolimus, which inhibit the mTOR pathway involved in cell growth and proliferation, but it is not the mechanism of action of muromonab.
Understanding the mechanism of action of immunosuppressive drugs like muromonab is essential for healthcare professionals involved in the care of transplant patients. Knowing how these medications work can help in optimizing therapy, managing side effects, and ultimately improving patient outcomes.
Option B) Binds to FK-binding protein is incorrect because this mechanism refers to drugs like tacrolimus and cyclosporine, which act by inhibiting calcineurin and preventing the production of interleukin-2 (IL-2).
Option C) Binds to IL-2 receptors on T cells is incorrect because muromonab does not directly target IL-2 receptors but rather binds to CD3 to block T cell activation, subsequently affecting IL-2 production.
Option D) Binds to mTOR is incorrect because this mechanism refers to drugs like sirolimus and everolimus, which inhibit the mTOR pathway involved in cell growth and proliferation, but it is not the mechanism of action of muromonab.
Understanding the mechanism of action of immunosuppressive drugs like muromonab is essential for healthcare professionals involved in the care of transplant patients. Knowing how these medications work can help in optimizing therapy, managing side effects, and ultimately improving patient outcomes.